ASCO 2023 | Advancements in targeted therapies for oncogene-driven resectable NSCLC

Samuel Rosner, MD, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, talks on the most significant advancements in targeted therapies for specific oncogene driver mutations in resectable non-small cell lung cancer (NSCLC). Dr Rosner highlights exploring the advantages of administering targeted therapies before or after surgery in oncogene-driven resectable NSCLC. While current practice involves neoadjuvant use for patients without EGFR or ALK alterations, the impressive data from the Phase III ADAURA ( NCT02511106) trial has sparked interest in post-operative therapy. The key question is whether these therapies can not only improve progression-free survival but also impact overall survival and recurrence patterns. Intracranial recurrence, which has significant clinical implications, could potentially be delayed with targeted therapies like osimertinib, as demonstrated in the Ardura trial. Additionally, the optimal duration of therapy remains an ongoing question, with trial designs often arbitrary. Determining the optimal duration will be a focus of research in the coming years. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.